IP Library Granted Patent US 7,879,349
Granted Patent B2
US 7,879,349 · App. 12/079,875 · Granted Feb 1, 2011

Cyanocobalamin low viscosity aqueous formulations for intranasal delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,879,349
App. No.
12/079,875
Granted
Feb 1, 2011
Kind
B2
Abstract

A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

Claims (17)

1. A stable pharmaceutical aqueous solution of cyanocobalamin comprised of cyanocobalamin and water, a preservative selected from the group consisting of benzyl alcohol, parabens, chlorobutanol, benzethonium chloride, and benzalkonium chloride, and combinations thereof, and a buffer selected from the group consisting of citric acid, sodium citrate, monopotassium phosphate, disodium phosphate, potassium biphthalate, sodium hydroxide, sodium acetate, acetic acid, and combinations thereof, wherein said solution of cyanocobalamin is suitable for intranasal administration, and has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin, with the proviso that the solution contains no mercury or mercury compounds.

2. The aqueous solution of claim 1 , wherein the pH of the solution is about 4-6.

3. The aqueous solution of claim 2 , wherein the pH of the solution is about 5.

4. The aqueous solution of claim 1 , wherein the preservative is benzyl alcohol.

5. The aqueous solution of claim 1 , wherein the preservative is benzalkonium chloride.

6. The aqueous solution of claim 1 , wherein the buffer is sodium hydroxide.

7. The aqueous solution of claim 1 , wherein the preservatives are benzyl alcohol and benzalkonium chloride and the buffer is sodium hydroxide.

8. The aqueous solution of claim 1 , wherein the cyanocobalamin is present at a concentration of about 0.5% of the total weight of the aqueous solution.

9. A method for administering cyanocobalamin comprised of infusing the nose with an aqueous solution of claim 1 .

10. The method of claim 9 , wherein the pH of the aqueous solution is about 4-6.

11. The method of claim 9 , wherein the pH of the aqueous solution is about 5.

12. The method of claim 9 , wherein the preservative is benzyl alcohol.

13. The method of claim 9 , wherein the preservative is benzalkonium chloride.

14. The method of claim 9 , wherein the buffer is sodium hydroxide.

15. The method of claim 9 , wherein the preservatives are benzyl alcohol and benzalkonium chloride and the buffer is sodium hydroxide.

16. The method of claim 9 , wherein the cyanocobalamin is present at a concentration of about 0.5% of the total weight of the aqueous solution.

17. A method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally an aqueous solution of claim 1 .

Assignments (15)
SECURITY INTEREST Recorded Jul 22, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 068469/0001 →
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: GOLDMAN SACHS BANK USA
Reel/Frame 068461/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2024
From: ENDO USA, INC.
To: ENDO OPERATIONS LIMITED
Reel/Frame 067245/0492 →
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2024
From: ENDO PHARMACEUTICALS INC.
To: ENDO USA, INC.
Reel/Frame 067203/0398 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ASTORA WOMEN'S HEALTH LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS INC.; PAR PHARMACEUTICAL, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2017
From: PAR PHARMACEUTICAL, INC.; ENDO PAR INNOVATION COMPANY, LLC
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 043118/0747 →
SECURITY INTEREST Recorded Jun 8, 2017
From: PAR PHARMACEUTICAL, INC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042743/0216 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: PAR PHARMACEUTICAL, INC.; ENDO GENERICS HOLDINGS, INC.; INNOTEQ, INC.
Reel/Frame 042171/0036 →
RELEASE OF SECURITY INTEREST Recorded Sep 30, 2015
From: BANK OF AMERICA, N.A.
To: PAR PHARMACEUTICAL, INC.; INNOTEQ, INC.; PAR PHARMACEUTICAL COMPANIES, INC.
Reel/Frame 036695/0782 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 25, 2015
From: PAR PHARMACEUTICAL, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 036687/0821 →
SECURITY AGREEMENT Recorded Oct 1, 2012
From: PAR PHARMACEUTICAL COMPANIES, INC.; PAR PHARMACEUTICAL, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 029061/0252 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2009
From: FULL CIRCLE PARTNERS, LP; FCC, LLC
To: QOL MEDICAL, LLC
Reel/Frame 022482/0149 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2009
From: QOL MEDICAL, LLC
To: PAR PHARMACEUTICAL, INC.
Reel/Frame 022482/0155 →